Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 3/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14553998 | 1.00 | TSHR (0.38) | TSHRALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL13663803 | 1.00 | TSHR (0.38) | TSHRALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL26199755 | 0.80 | TLR8 (0.34) | CYP2D6SMN1; SMN2KCNA5KCNH2 | |
| SCHEMBL454826 | 0.77 | NOS3 (0.30) | — | |
| SCHEMBL5272426 | 0.77 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL20472673 | 0.77 | TRPA1 (0.34) | TSHRALDH1A1NPC1RAB9ATDP1 | |
| SCHEMBL453189 | 0.77 | HDAC8 (0.33) | NPC1RAB9AMEN1KMT2AHDAC8 | |
| SCHEMBL8683581 | 0.77 | TAAR1 (0.44) | ALDH1A1 | |
| SCHEMBL453190 | 0.77 | TRPA1 (0.34) | TSHRALDH1A1NPC1RAB9ATDP1 | |
| SCHEMBL16677129 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230109865-A1 | Chemical Process for the Preparation of Herbicidal Pyridazine Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2023-04-13 | — | — | US | disclosed |
| US-11575088-B2 | Composition of matter for use in organic light-emitting diodes | KYULUX, INC. (JP) | 2023-02-07 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11325930-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210403462-A1 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8097612-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7955718-B2 | Organic EL element and process for manufacture of organic EL element | TDK CORPORATION (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7662971-B2 | enzyme inhibitor for treating sleep disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100004227-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1549624-B1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | SCRIPPS RESEARCH INST (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325930-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | TSHR 11/4885ALDH1A1 2149/4885NPC1 4279/4885 |
| US-20100004227-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | BAX, BAD, BAK1 | TSHR 2437/4885ALDH1A1 2673/4885NPC1 1771/4885 |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | TSHR 3026/4885ALDH1A1 3834/4885NPC1 3297/4885 |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | TSHR 4432/4885ALDH1A1 332/4885NPC1 3218/4885 |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | BCL6B, BCL6, BLK | TSHR 2407/4885ALDH1A1 3788/4885NPC1 1352/4885 |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | TSHR 1410/4885ALDH1A1 1721/4885NPC1 811/4885 |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | OPRD1, OPRK1, OPRL1 | TSHR 924/4885ALDH1A1 673/4885NPC1 83/4885 |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | TSHR 2610/4885ALDH1A1 3476/4885NPC1 2892/4885 |
| US-11575088-B2 | Composition of matter for use in organic light-emitting diodes | CRY2, CYBA, ALDH1A2 | TSHR 4759/4885ALDH1A1 116/4885NPC1 864/4885 |
| US-20210403462-A1 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | DDT, ACHE, NIT2 | TSHR 1434/4885ALDH1A1 1091/4885NPC1 2699/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | TSHR 3622/4885ALDH1A1 865/4885NPC1 3526/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | TSHR 2101/4885ALDH1A1 2861/4885NPC1 2326/4885 |
| US-20230109865-A1 | Chemical Process for the Preparation of Herbicidal Pyridazine Compounds | DHFR, DDT, DHPS | TSHR 2559/4885ALDH1A1 77/4885NPC1 4443/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TSHR 4640/4885ALDH1A1 1171/4885NPC1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.